Market Place
Sourcing Support
All News #Library
Biotech
Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog
28 Mar 2026 //
PR NEWSWIRE
Otsuka Unveil New Repinatrabit Open-Label Data in Phenylketonuria
12 Mar 2026 //
BUSSINESSWIRE
Biodexa Announces Exclusive License of Otsuka’s OPB-171775
06 Feb 2026 //
GLOBENEWSWIRE
Otsuka Pharma Seeks FDA Approval For Centanafadine In ADHD
24 Nov 2025 //
BUSINESSWIRE
Otsuka inks $613M deal for Swedish Biotech`s IL1RAP Antibodies
17 Jul 2025 //
FIERCE BIOTECH
AN Venture Partners Announces Final Close of $200M Fund I
02 Jul 2025 //
BUSINESSWIRE
Harbour BioMed, Otsuka Partner to Advance BCMAxCD3 T-Cell Engager
23 Jun 2025 //
PR NEWSWIRE
Otsuka`s Kidney Disease Trial Results Heat up Battle with Vera
07 Jun 2025 //
BUSINESSWIRE
Otsuka`s BLA for Sibeprenlimab in IgAN Accepted by FDA
27 May 2025 //
BUSINESSWIRE
Mosaic licenses 2 clinical stage tumor drugs from Otsuka`s Astex
24 Apr 2025 //
FIERCE BIOTECH
Otsuka Files BLA for Sibeprenlimab in Immunoglobulin A Nephropathy
31 Mar 2025 //
BUSINESSWIRE
Otsuka Updates on Sibeprenlimab for IgA Nephropathy
19 Nov 2024 //
BUSINESSWIRE
Otsuka`s kidney disease drug improves UPCR levels in phase 3 trial
23 Oct 2024 //
BUSINESSWIRE
Lundbeck blames DTC blackout for slowdown in Rexulti growth
16 May 2024 //
FIERCE PHARMA
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation
16 Feb 2024 //
BUSINESSWIRE
Otsuka Submits New Drug Application in Japan for Voclosporin
10 Nov 2023 //
PRESS RELEASE
New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab
06 Nov 2023 //
PRESS RELEASE
Journal of Medicine Publishes Complete Results of Phase 2 Trial of Sibeprenlimab
02 Nov 2023 //
BUSINESSWIRE
FDA accepts one, delays another; Data, deals and dollars for slate of biotechs
09 Jan 2023 //
ENDPTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.